The site-specific higher-molecular-weight PEGylated variant also shows promise for the same-day administration of the G-CSF drug, which is a challenge in the current G-CSF therapy regimen in the treatment of chemotherapy-induced neutropenia. This evidence concerns the gene CSF3 and neutropenia.